What Did the Trial Find?
The trial found that more than 41 percent of patients had a reduction in tumor size. For those patients taking pemetrexed and another chemotherapy drug known as cisplatin, researchers found that the survival rate was extended by as much as three months.
Thanks to Dr. Nicholas Vogelzang, many patients have enjoyed improved prognosis and quality of life.
Other Trials
Dr. Nicholas Vogelzang has remained ever-involved in clinical trials. He was involved in a clinical trial for a drug known as Alimta. This drug was one of the first and only drugs approved by the FDA to treat mesothelioma. Dr. Vogelzang also works as the editor for Malignant Mesothelioma, a clinical textbook that is highly comprehensive about the latest and most up-to-date information on the subject.
Speaking With a Doctor About the Diagnosis
One of the best ways to learn about treatment is to speak with Dr. Vogelzang directly. He will consider some of the latest therapies for your disease. Thanks to Dr. Vogelzang, many patients have enjoyed improved prognosis and quality of life. Contact Dr. Nicholas Vogelzang to discuss your treatment options and how to proceed in a way that best suits you.
Rae Steinbach
Lauren Weinand